Klinnert, Sarah http://orcid.org/0000-0002-1604-7917
Schenkel, Corinne D.
Freitag, Patrick C.
Günthard, Huldrych F.
Plückthun, Andreas http://orcid.org/0000-0003-4191-5306
Metzner, Karin J. http://orcid.org/0000-0003-4862-1503
Funding for this research was provided by:
Gilead Sciences (00408)
Novartis Foundation (FN20-0000000206)
Article History
Received: 15 February 2023
Revised: 12 July 2023
Accepted: 26 July 2023
First Online: 9 August 2023
Competing interests
: KJM has received travel grants and honoraria from Gilead Sciences, Roche Diagnostics, GlaxoSmithKline, Merck Sharp & Dohme, Bristol-Myers Squibb, ViiV and Abbott; and the University of Zurich received research grants from Gilead Science, Novartis, Roche, and Merck Sharp & Dohme for studies that Dr. Metzner serves/served as principal investigator, and advisory board honoraria from Gilead Sciences. HFG has been an advisor/consultant or a Data Safety Monitoring Board member to Gilead Sciences, Merck, ViiV, GSK, Janssen and Novartis and has received unrestricted research grants from Gilead Sciences. AP is a cofounder and shareholder of Vector BioPharma that commercializes the targeted and shielded adenovirus technology. The other authors declare no conflicts of interest.